China authorizes subcutaneous LEQEMBI for early Alzheimer's treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-03
Category: health
Source: GlobeNewswire
Original source

China has approved the subcutaneous version of LEQEMBI (lecanemab) for initiating treatment in patients with early Alzheimer's disease. This follows similar U.S. FDA approvals in 2025 and 2026, based on positive data from the Clarity AD clinical trial. This approval expands access to a new administration method for an Alzheimer's treatment in a major market.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai